Does the media favor AMLX or SLN?

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Silence Therapeutics. MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.00 beat Amylyx Pharmaceuticals' score of 0.95 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLN or KLRA?

In the previous week, Silence Therapeutics and Silence Therapeutics both had 3 articles in the media. Silence Therapeutics' average media sentiment score of 1.00 beat Kailera Therapeutics' score of -0.33 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SLN or AGIO?

In the previous week, Agios Pharmaceuticals had 27 more articles in the media than Silence Therapeutics. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.00 beat Agios Pharmaceuticals' score of 0.41 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agios Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral

Is ZLAB or SLN more profitable?

Zai Lab has a net margin of -39.29% compared to Silence Therapeutics' net margin of -8,943.86%. Zai Lab's return on equity of -24.32% beat Silence Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% Silence Therapeutics -8,943.86% -105.34% -52.79%

Does the media refer more to ZLAB or SLN?

In the previous week, Zai Lab had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Zai Lab and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.00 beat Zai Lab's score of 0.11 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SLN or SION?

In the previous week, Silence Therapeutics and Silence Therapeutics both had 3 articles in the media. Sionna Therapeutics' average media sentiment score of 1.22 beat Silence Therapeutics' score of 1.00 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Silence Therapeutics (SLN) Competitors

$11.28 +0.60 (+5.62%)

As of 11:43 AM Eastern

Compare

SLN vs. AMLX, KLRA, AGIO, ZLAB, and SION

Should you buy Silence Therapeutics stock or one of its competitors? MarketBeat compares Silence Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silence Therapeutics include Amylyx Pharmaceuticals (AMLX), Kailera Therapeutics (KLRA), Agios Pharmaceuticals (AGIO), Zai Lab (ZLAB), and Sionna Therapeutics (SION).

How does Silence Therapeutics compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Silence Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	27.52	-$144.74M	-$1.50	N/A
Silence Therapeutics	$560K	951.55	-$88.61M	-$1.59	N/A

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Silence Therapeutics. MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.00 beat Amylyx Pharmaceuticals' score of 0.95 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals currently has a consensus price target of $25.38, suggesting a potential upside of 17.35%. Silence Therapeutics has a consensus price target of $55.00, suggesting a potential upside of 387.59%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Amylyx Pharmaceuticals has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Silence Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Kailera Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Kailera Therapeutics (NASDAQ:KLRA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

98.7% of Silence Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Silence Therapeutics and Silence Therapeutics both had 3 articles in the media. Silence Therapeutics' average media sentiment score of 1.00 beat Kailera Therapeutics' score of -0.33 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kailera Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Kailera Therapeutics' return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Kailera Therapeutics	N/A	N/A	N/A

Silence Therapeutics currently has a consensus target price of $55.00, suggesting a potential upside of 387.59%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 141.53%. Given Silence Therapeutics' higher probable upside, research analysts plainly believe Silence Therapeutics is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Kailera Therapeutics has lower revenue, but higher earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	951.55	-$88.61M	-$1.59	N/A
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A

Summary

Silence Therapeutics and Kailera Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Silence Therapeutics compare to Agios Pharmaceuticals?

Silence Therapeutics (NASDAQ:SLN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Agios Pharmaceuticals has a net margin of -418.24% compared to Silence Therapeutics' net margin of -8,943.86%. Agios Pharmaceuticals' return on equity of -35.67% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Silence Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Silence Therapeutics currently has a consensus target price of $55.00, indicating a potential upside of 387.59%. Agios Pharmaceuticals has a consensus target price of $40.88, indicating a potential upside of 32.03%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Silence Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

Silence Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Silence Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	951.55	-$88.61M	-$1.59	N/A
Agios Pharmaceuticals	$98.34M	18.72	-$412.78M	-$7.01	N/A

In the previous week, Agios Pharmaceuticals had 27 more articles in the media than Silence Therapeutics. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.00 beat Agios Pharmaceuticals' score of 0.41 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral

98.7% of Silence Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Silence Therapeutics beats Agios Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Silence Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.54	-$175.54M	-$1.62	N/A
Silence Therapeutics	$560K	951.55	-$88.61M	-$1.59	N/A

In the previous week, Zai Lab had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Zai Lab and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.00 beat Zai Lab's score of 0.11 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zai Lab has a net margin of -39.29% compared to Silence Therapeutics' net margin of -8,943.86%. Zai Lab's return on equity of -24.32% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

Zai Lab currently has a consensus target price of $40.00, indicating a potential upside of 117.85%. Silence Therapeutics has a consensus target price of $55.00, indicating a potential upside of 387.59%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Zai Lab has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Summary

Silence Therapeutics beats Zai Lab on 9 of the 15 factors compared between the two stocks.

How does Silence Therapeutics compare to Sionna Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Sionna Therapeutics (NASDAQ:SION) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Silence Therapeutics presently has a consensus price target of $55.00, suggesting a potential upside of 387.59%. Sionna Therapeutics has a consensus price target of $53.22, suggesting a potential upside of 5.07%. Given Silence Therapeutics' higher probable upside, research analysts clearly believe Silence Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

98.7% of Silence Therapeutics shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sionna Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Sionna Therapeutics' return on equity of -27.31% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Silence Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

In the previous week, Silence Therapeutics and Silence Therapeutics both had 3 articles in the media. Sionna Therapeutics' average media sentiment score of 1.22 beat Silence Therapeutics' score of 1.00 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics has lower revenue, but higher earnings than Silence Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	951.55	-$88.61M	-$1.59	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Summary

Sionna Therapeutics beats Silence Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export

Metric	Silence Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$532.02M	$3.53B	$6.80B	$12.89B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-7.08	7.33	279.90	25.40
Price / Sales	951.55	1,274.10	648.58	114.39
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	8.55	17.12	11.10	6.30
Net Income	-$88.61M	-$12.52M	$3.48B	$347.60M
7 Day Performance	-2.34%	1.54%	1.93%	2.53%
1 Month Performance	8.57%	-6.32%	-3.29%	-2.57%
1 Year Performance	89.58%	49.25%	62.38%	20.26%

Silence Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	3.4705 of 5 stars	$11.28 +5.6%	$55.00 +387.6%	+73.1%	$532.02M	$560K	N/A	100	Upcoming Earnings Gap Up
AMLX Amylyx Pharmaceuticals	4.0282 of 5 stars	$19.55 +0.3%	$24.63 +26.0%	+161.3%	$2.17B	$87.37M	N/A	200	News Coverage Upcoming Earnings Analyst Forecast High Trading Volume
KLRA Kailera Therapeutics	2.9085 of 5 stars	$16.74 -4.2%	$42.75 +155.4%	N/A	$2.17B	N/A	N/A	145
AGIO Agios Pharmaceuticals	2.8029 of 5 stars	$35.99 -2.7%	$40.00 +11.1%	-12.7%	$2.14B	$54.03M	N/A	390	Earnings Report Analyst Revision
ZLAB Zai Lab	3.3921 of 5 stars	$18.62 -0.1%	$40.00 +114.8%	-50.6%	$2.12B	$460.16M	N/A	1,784	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. AMLX, KLRA, AGIO, ZLAB, and SION

How does Silence Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does Silence Therapeutics compare to Kailera Therapeutics?

Summary

How does Silence Therapeutics compare to Agios Pharmaceuticals?

Summary

How does Silence Therapeutics compare to Zai Lab?

Summary

How does Silence Therapeutics compare to Sionna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. AMLX, KLRA, AGIO, ZLAB, and SION

How does Silence Therapeutics compare to Amylyx Pharmaceuticals?

Which has better valuation and earnings, AMLX or SLN?

Does the media favor AMLX or SLN?

Do analysts rate AMLX or SLN?

Do insiders & institutionals hold more shares of AMLX or SLN?

Is AMLX or SLN more profitable?

Which has more volatility and risk, AMLX or SLN?

Summary

How does Silence Therapeutics compare to Kailera Therapeutics?

Do institutionals & insiders have more ownership in SLN or KLRA?

Does the media favor SLN or KLRA?

Is SLN or KLRA more profitable?

Do analysts recommend SLN or KLRA?

Which has better earnings and valuation, SLN or KLRA?

Summary

How does Silence Therapeutics compare to Agios Pharmaceuticals?

Is SLN or AGIO more profitable?

Which has more risk & volatility, SLN or AGIO?

Do analysts prefer SLN or AGIO?

Which has higher valuation and earnings, SLN or AGIO?

Does the media refer more to SLN or AGIO?

Do insiders and institutionals hold more shares of SLN or AGIO?

Summary

How does Silence Therapeutics compare to Zai Lab?

Which has better valuation & earnings, ZLAB or SLN?

Does the media refer more to ZLAB or SLN?

Do insiders & institutionals hold more shares of ZLAB or SLN?

Is ZLAB or SLN more profitable?

Do analysts recommend ZLAB or SLN?

Which has more risk & volatility, ZLAB or SLN?

Summary

How does Silence Therapeutics compare to Sionna Therapeutics?

Do analysts rate SLN or SION?

Do institutionals & insiders have more ownership in SLN or SION?

Is SLN or SION more profitable?

Which has more volatility & risk, SLN or SION?

Does the media favor SLN or SION?

Which has stronger earnings and valuation, SLN or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools